Ethicon pushes for completion of tissue adhesive trials:
This article was originally published in Clinica
Ethicon has given Protein Polymer Technologies until the end of the year to complete trials of its tissue adhesives (see Clinica No 673, p 1). If they are successful, Ethicon will continue to contribute to on-going R&D and regulatory costs. Ethicon and Johnson & Johnson Development, both Johnson & Johnson subsidiaries, have provided an additional $735,000 in R&D expenses. Ethicon has worldwide marketing rights and Johnson & Johnson Development has warrants for some of the biomaterials company's common stock.
You may also be interested in...
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.
As Chinese returnees transform their startups to fully-fledged biopharma operations with a full product lineup and the global market in sight, the journey has been filled with challenges. Based on interviews and on-the-ground reporting, this new series takes a closer look at several companies' experiences.
US FDA Will Need About A Week To Complete COVID Vaccine Assessment Following Advisory Cmte., CBER’s Marks Says
Timeline is the most pessimistic public projection to date, but still incredibly fast. Clinical trial patients on placebo could be contacted and offered the vaccine after an EUA is granted.